Skip to content

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

Dennis J. Slamon, Gary M. Clark, Steven Wong, Wendy Jo Levin, Axel Ullrich, William Leo McGuire

Science · 1987 · 11,862 citations

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Slamon, D. J., Clark, G. M., Wong, S., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science, 235(4785), 177–182. https://doi.org/10.1126/science.3798106

In text: (Slamon et al., 1987)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.

  1. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER22001
  2. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib2004
  3. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy2004
  4. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer1989
  5. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer2017

Metadata from OpenAlex (CC0). Citations are generated from the published record.